184 results on '"Dalban, C"'
Search Results
2. 184P Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study
3. 674P Initial curative management for localized/locally advanced head and neck squamous cell carcinomas (LAHNSCC): Exclusive (chemo)radiation (CRT) or S/IC (surgery or induction chemotherapy) – The EPOCKS study
4. 1480P Baseline levels of proinflammatory cytokines according to body mass index (BMI) and BMI impact on clinical outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (NIVO) within the NIVOREN trial
5. 528MO Is re-introduction or continuation of PARP inhibitors after local therapy for oligo-metastatic progression in patients with relapsed ovarian cancer relevant?
6. 465P Larotracking: Real-life study of locally advanced/metastatic solid tumor treated with larotrectinib in French expanded access program
7. Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF
8. Ré-irradiations des cancers de la tête et du cou : état du concept et voies de développement
9. FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial
10. 697P Impact of β-blockers (BB) on outcomes of metastatic renal cell carcinoma (mRCC) patients treated with nivolumab (N)
11. 657MO Antibiotic (ATB) therapy and outcome from nivolumab (N) in metastatic renal cell carcinoma (mRCC) patients (pts): Results of the GETUG-AFU 26 NIVOREN multicentric phase II study
12. 687P NIVOREN GETUG-AFU 26 translational study: Baseline peripheral cytokines predict survival in metastatic clear cell renal carcinoma (RCC) treated with nivolumab
13. 689P Human leukocyte antigen (HLA) class I/II expression as a predictive biomarker for response to immune oncology (IO) therapy in metastatic clear-cell renal cell carcinoma (m-ccRCC)
14. FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial
15. NIVOREN GETUG-AFU 26 translational study: Baseline peripheral cytokines predict survival in metastatic clear cell renal carcinoma (RCC) treated with nivolumab
16. Human leukocyte antigen (HLA) class I/II expression as a predictive biomarker for response to immune oncology (IO) therapy in metastatic clear-cell renal cell carcinoma (m-ccRCC)
17. 1909P Baseline cytokine levels according to the line of treatment in patients with metastatic clear cell renal cell carcinoma treated with nivolumab: NIVOREN GETUG-AFU 26 translational study
18. Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N)
19. 712P Primary tumour response in patients treated with nivolumab for metastatic renal cell carcinoma (mRCC): Results of the GETUG-AFU 26 NIVOREN trial
20. 700O Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N)
21. The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach
22. Romanian Code for the Design of Steel Structures Subjected to Seismic Loads
23. Behavior of Steel Concentrically Braced Frames with Friction Disipation Devices
24. NIVOREN GETUG-AFU 26 translational study: CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N)
25. Peut-on proposer une radiothérapie à visée curative pour les patients de plus de 80 ans atteints d’un adénocarcinome prostatique ? Expérience chez 95 patients
26. Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma
27. EP-1641 Radiotherapy for prostate cancer patients over 80 years: 95 patients treated in a single institution
28. HOW TO BECOME A POLITICIAN. THE ROLE OF EDUCATIONAL BACKGROUND AND ACADEMIC ACHIEVEMENT IN ROMANIA.
29. Brain metastases response to nivolumab in patients with renal cell carcinoma (RCC): Prospective analysis from the GETUG-AFU 26 (NIVOREN) trial
30. Alienor/ENGOT-ov7 randomized trial exploring weekly paclitaxel (wP) + bevacizumab (bev) vs wP alone for patients with ovarian sex cord tumors (SCT) in relapse
31. 966P - Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma
32. 909PD - NIVOREN GETUG-AFU 26 translational study: CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N)
33. Correlation between radio-induced lymphocyte apoptosis measurements obtained from two French centres
34. A phase I dose escalation study using simultaneous integrated-boost IMRT with temozolomide in patients with unifocal glioblastoma
35. 934O - Alienor/ENGOT-ov7 randomized trial exploring weekly paclitaxel (wP) + bevacizumab (bev) vs wP alone for patients with ovarian sex cord tumors (SCT) in relapse
36. 868PD - Brain metastases response to nivolumab in patients with renal cell carcinoma (RCC): Prospective analysis from the GETUG-AFU 26 (NIVOREN) trial
37. Impact de la chirurgie de clôture sur la qualité de vie après chimioradiothérapie et curiethérapie des cancers du col utérin localement évolués
38. 2069 Elective nodal irradiation during exclusive chemoradiation for locally-advanced esophageal cancer: IMRT better spares critical organs at risk
39. Prescriptions médicales de patients en soins palliatifs dans un centre régional de lutte contre le cancer
40. 2009 Tumoral lymphocyte immune response to preoperative radiotherapy in locally advanced rectal cancer as a prognostic factor for survival: The LYMPHOREC study
41. Impact du bévacizumab ajouté à un traitement de radiochimiothérapie par témozolamide sur le temps jusqu’à détérioration de la qualité de vie chez des patients atteints d’un glioblastome non résécable
42. Neuropsychiatric burden after Chikungunya outbreak observed in the population-based TELECHIK cohort study
43. Chimioradiothérapie exclusive ganglionnaire prophylactique chez les patients traités dans les cancers de l’œsophage localement évolués : la radiothérapie avec modulation d’intensité épargne mieux les organes à risque
44. Cancer de la prostate localisé et radiothérapie conformationnelle avec modulation d’intensité : quels sont les paramètres dosimétriques les plus pertinents pour prédire la toxicité digestive aiguë ?
45. Étude du différentiel volumétrique et géométrique des différents lobes pulmonaires entre blocage volontaire de la respiration et respiration libre
46. The Relationship Between the Occurrence of Bone Metastases and Dose/Volume of Prior Prostate Radiation Therapy in Patients With Localized Prostate Cancer
47. Étude de la relation dose–toxicité d’une chimioembolisation à base d’idarubicine et de microsphères d’embolisation dans le traitement du carcinome hépatocellulaire
48. Comparaison des réirradiations conformationnelles avec modulation d’intensité des carcinomes de la tête et du cou selon le schéma de Vokes et le schéma monofractionné
49. RCMI contre radiothérapie conformationnelle tridimensionnelle chez les patients traités pour un cancer du canal anal : quel bénéfice clinique ?
50. Sarcopenia Affects Treatment Toxicity in Metastatic Colorectal Cancer Patients: Results of a Prospective Multicenter Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.